Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 1308

Next Previous
Drug Profile

BAT 1308

Alternative Names: BAT-1308; Recombinant humanized anti PD-1 monoclonal antibody injection

Latest Information Update: 08 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Cervical cancer; Endometrial cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 07 Aug 2025 Bio Thera Solutions terminates phase II/III trial in Endometrial cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent) in China (IV) (NCT06321068)
  • 30 May 2025 Adverse events and efficacy data data from a phase II/III trial in Cervical cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO) .
  • 12 Apr 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT06341114)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top